Trial 9L-23-5


A Phase 1/2, Open-label, Dose-Escalation and Dose-Expansion Cohort Study of SNDX-5613 in Patients with Relapsed/Refractory Leukemias, Including Those Harboring an MLL/KMT2A Gene Rearrangement or Nucleophosmin 1 (NPM1) Mutation

Type: Treatment
Phase: Phase I/II
Status: Open to Accrual
Treatments: Biological Response Modifier, Chemotherapy: Systemic
Randomized: No
USC Satellite Location: None
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  George Yaghmour, M.D.
Other Trial Staff:  Christine Duran, Coordinator, Mary Ordaz, D.M., Niranjan Bhatt, D.M., Donna Fernando, Coordinator, Nelli Dimitrova, D.M., Hannah Trey, Coordinator, Sonny Tong, D.M., Jenny Kim, D.M., Aliya Anvery, Coordinator, Rhiannon Imbeah, D.M.

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.